Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses

Journal of Clinical Oncology

Volumn 33, Issue 15, 2015, Pages 1674-1679

  Ford, Patricia A ^a   Grant, Shakira J ^a   Mick, Rosemarie ^a   Keck, Gina ^a  

^a PENNSYLVANIA HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; CARMUSTINE; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IRON; MELPHALAN; PHYTOMENADIONE; ANTINEOPLASTIC AGENT; HEMOGLOBIN;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLEEDING; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; FEMALE; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN DETERMINATION; HUMAN; JEHOVAH'S WITNESS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; AUTOTRANSPLANTATION; BIOSYNTHESIS; BLOOD TRANSFUSION; HEMATOLOGIC NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PROCEDURES; RECURRENT DISEASE; STEM CELL TRANSPLANTATION; YOUNG ADULT;

ADULT; AGED; AMINOCAPROIC ACID; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD TRANSFUSION; CARMUSTINE; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; ETOPOSIDE; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOLOGIC NEOPLASMS; HEMOGLOBINS; HUMANS; IRON; JEHOVAH'S WITNESSES; LYMPHOMA; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; VITAMIN K 1; YOUNG ADULT;

EID: 84933557712     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.57.9912     Document Type: Article

References (23)

1. Attal M, Harousseau JL, Stoppa AM, et al: A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91-97, 1996
2. Child JA, Morgan GJ, Davies FE, et al: Highdose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875-1883, 2003
3. Phillip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
4. Nademanee A, Molina A, Dagis A, et al: Autologous stem-cell transplantation for poor-risk and relapsed intermediate-and high-grade non-Hodgkin's lymphoma. Clin Lymphoma 1:46-54, 2000
5. Schmitz N, Pfistner B, Sextro M, et al: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomized trial. The Lancet 359:2065-2071, 2002
6. Gertz MA, Ansell SM, Dingli D, et al: Autologous stem-cell transplant in 716 patients with multiple myeloma: Low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative. Mayo Clin Proc 83:1131-1138, 2008
7. Viviani S, Di Nicola M, and Bonfante V: Longterm results of high-dose chemotherapy with autologous bone marrow or peripheral stem-cell transplant as first salvage treatment for relapsed or refractory Hodgkin lymphoma: A single institution experience. Leuk Lymphoma 51:1251-1259, 2010
8. Tichelli A, Bhatia S, Socié G: Cardiac and cardiovascular consequences after haematopoietic stem-cell transplantation. Br J Haematol 142:11-26, 2008
9. Horacek JM, Jebavy L, Jakl M, et al: Cardiovascular changes associated with infusion of hematopoietic cell grafts in oncohematological patients-impact of cryopreservation with dimethylsulfoxide. Experimental Oncology 31:121-122, 2009
10. Feliz V, Saiyad S, Ramarao S, et al: Melphalan-induced supraventricular tachycardia: Incidence and risk factors. Clin Cardiol 34:356-359, 2011
11. Mileshkin LR, Seymour JF, Wolf MM, et al: Cardiovascular toxicity is increased, but manageable, during high-dose chemotherapy and autologous peripheral blood stem-cell transplantation for patients aged 60 years and older. Leukemia Lymphoma 46, 11:1575-1579, 2005
12. Hidalgo JD, Krone R, Rich MW, et al: Supraventricular tachyarrhythmias after hematopoietic stem-cell transplantation: Incidence, risk factors, and outcomes. Bone Marrow Transplant 34:615-619, 2004
13. Brockstein BE, Smiley C, Al-Adir J, et al: Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: Prognostic factors. Bone Marrow Transplant 25:885-894, 2000
14. Guglin M, Aljayeh M, Saiyad S, et al: Introducing a new entity: Chemotherapy-induced arrhythmia. Europace 11:1579-1586, 2009
15. Sakata-Yanagimoto M, Kanda Y, Nakagawa M, et al: Predictors for severe cardiac complications after hematopoietic stem-cell transplantation. Bone Marrow Transplant 33:1043-1047, 2004
16. Stillwell EE, Wessler JD, Rebolledo BJ, et al: Retrospective outcome data for hematopoietic stem-cell transplantation in patients with concurrent coronary artery disease. A Biol Blood Marrow Transplant 17:1182-1186, 2011
17. Fujimaki K, Maruta A, Yoshida M, et al: Posttransplant complications-Severe cardiac toxicity in hematological stem-cell transplantation: Predictive value of reduced left ventricular ejection fraction. Bone Marrow Transplant 27:307-310, 2001
18. Lehmann S, Isberg B, Ljungman P, et al: Cardiac systolic function before and after hematopoietic stem-cell transplantation. Bone Marrow Transplant 26:187-192, 2000
19. Schiffer CA, Anderson KC, Bennett CL, et al: Platelet transfusions for patients with cancer: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519-1538, 2001
20. Rebulla P, Finazzi G, Marangoni F, et al: The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. N Engl J Med 337:1870-1875, 1997
21. Wandt H, Schaefer-Eckart K, Frank M, et al: A therapeutic platelet transfusion strategy is safe and feasible in patients after autologous peripheral blood stem-cell transplantation. Bone Marrow Transplant 37:387-392, 2006
22. Wandt H, Wendelin K, Schaefer-Eckart K, et al: A therapeutic platelet transfusion strategy without routine prophylactic transfusion is feasible and safe and reduces platelet transfusion numbers significantly: Preliminary analysis of a randomized study in patients after high dose chemotherapy and autologous peripheral blood stem-cell transplantation. Blood (ASH Annual Meeting Abstracts), 112, 2008 (abst 286).
23. Stanworth SJ, Estcourt LJ, Powter G, et al: A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med 368(19):1771-1780, 2013